Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.2 RMB per 10 shares to all shareholders, based on the total share capital excluding repurchased shares of 11,913,139 shares[5]. - The board of directors has approved the profit distribution plan, emphasizing the commitment to shareholder returns[5]. - The company has implemented a stable profit distribution policy, with a cash dividend amount of ¥18,226,662.34, representing 100% of the total profit distribution[194]. - The net profit for the parent company in 2023 was ¥16,843,405.01, after allocating ¥1,684,340.50 to surplus reserves[194]. - The total distributable profit available for shareholders was ¥2,189,322,816.79, with the previous year's undistributed profit being ¥2,266,488,377.88[194]. - The company has not proposed a cash dividend distribution plan despite having positive distributable profits[194]. - The company’s cash dividend per 10 shares is ¥0.2, with no stock dividends issued[194]. - The company’s cash dividend policy aligns with its mature development stage and aims to enhance investor returns[194]. Financial Performance - The company’s operating revenue for 2023 was ¥6,442,152,833.02, a decrease of 18.10% compared to ¥7,865,465,550.37 in 2022[21]. - The net profit attributable to shareholders for 2023 was -¥465,243,948.60, representing a decline of 166.76% from ¥696,838,439.53 in 2022[21]. - The net cash flow from operating activities increased by 68.67% to ¥1,077,406,421.58 in 2023, up from ¥638,760,811.35 in 2022[21]. - The total assets at the end of 2023 were ¥13,907,013,976.85, a decrease of 7.34% from ¥15,008,660,120.73 at the end of 2022[21]. - The net assets attributable to shareholders decreased by 7.33% to ¥6,441,634,199.75 at the end of 2023, down from ¥6,951,263,314.13 at the end of 2022[21]. - The basic earnings per share for 2023 was -¥0.5039, compared to ¥0.7548 in 2022, reflecting a significant decline[21]. - The total profit for 2023 was CNY -402.05 million, a decline of 142.57% year-on-year, while the net profit attributable to shareholders was CNY -465.24 million, a decrease of 166.76% compared to the previous year[68]. Research and Development - The company has a focus on research and development of new products and technologies, aiming to enhance its market position[5]. - The pharmaceutical R&D team expanded in 2023, with over 1/3 of employees holding master's or doctoral degrees, and developed more than 10 continuous process projects and 4 continuous photocatalysis projects[62]. - The company established a new R&D service (CRO) base in 2023 to enhance R&D capabilities and expanded its technical fields, including PROTAC, Linker, and GalNAc[62]. - The R&D team is committed to optimizing existing product processes and increasing the development of high-value and differentiated products to enhance core competitiveness[61]. - The company is actively participating in the development of innovative drugs, with a pipeline of clinically promising products in phases II and III[43]. - The company has established a multi-level R&D platform to promote rapid integration of process technology and engineering technology, improving market competitiveness of customized and proprietary products[57]. Market and Industry Trends - The company operates in the plant protection industry, which is characterized by high R&D barriers for patented products and intense competition in the non-patented product market[31]. - The global carbon reduction goals are driving the agricultural protection industry to develop more efficient and low-toxicity products, with an increasing demand for biological products and green production processes[32]. - The CDMO model is increasingly adopted by pharmaceutical companies to outsource R&D and production, providing more opportunities for CDMO firms to participate in the entire product supply chain[34]. - The domestic MAH system has created new opportunities for the pharmaceutical market and CDMO companies, enhancing their innovation and production capabilities[35]. - The demand for functional chemicals is rapidly expanding due to increasing needs for battery chemicals and new materials, driven by geopolitical factors and carbon neutrality strategies[36]. - The lithium battery market in China is projected to reach a shipment volume of 886 GWh in 2023, reflecting a year-on-year growth of 35%[131]. Corporate Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the meeting[5]. - The report outlines the company's governance structure and responsibilities of the board and management[5]. - The board of directors consists of seven members, with three independent directors, ensuring compliance with legal and regulatory requirements[160]. - The company has a transparent information disclosure system, ensuring timely and accurate communication with investors[161]. - The company has established a comprehensive internal control system, covering 15 subsidiaries, to ensure effective governance and compliance[198]. - The company has engaged in capital increases and employee stock ownership plans for its subsidiaries, including Shanghai Baofeng and Taizhou Lianhua[197]. Operational Performance and Strategy - The company is committed to compliance with safety, health, environment, and quality standards in its operations[5]. - The company is actively involved in the production of fine chemicals and pharmaceutical intermediates, contributing to its revenue streams[5]. - The company is focused on developing electronic chemicals, battery chemicals, and high-performance polymer materials, while maintaining a stable and high-quality product line[44]. - The company aims to maintain a competitive edge through continuous investment in engineering equipment upgrades and innovative technology applications[63]. - The company is focusing on process optimization for clients' existing products to maintain market competitiveness and has successfully applied unique technical capabilities in various projects[75]. - The company aims to build an end-to-end supply chain management system to maximize production resource utilization while ensuring order delivery capabilities[71]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 5,771, with 1,086 in the parent company and 4,685 in major subsidiaries[189]. - The company conducted 7,551 internal offline training sessions in 2023, totaling 12,230 hours and reaching 199,166 participants[192]. - Online learning totaled 136,668 hours with 40,272 participants in 2023[192]. - The company spent nearly 4.66 million yuan on various internal and external training consulting fees in 2023[192]. - The professional composition of employees includes 3,573 production personnel, 1,532 technical personnel, and 54 sales personnel[189]. - The company emphasizes a fair compensation policy based on internal, external, and individual fairness[190]. Future Outlook and Strategic Goals - The company aims to maintain industrial business revenue at no less than 2023 levels in 2024, although this target is subject to macroeconomic and market conditions[134]. - The company plans to enhance its core competitiveness by focusing on innovation and expanding its CDMO business, particularly in biopesticides and pharmaceuticals[133]. - In 2024, the company will continue to optimize costs in its pesticide business by improving production processes and introducing advanced environmental treatment technologies[138]. - The pharmaceutical segment is expected to grow steadily, with multiple client validation projects completed in 2023 and new project verifications planned for 2024[140]. - The company is committed to sustainable development and will strengthen its SHEQ&C management system to enhance its core competitiveness in safety, health, and environmental quality[135]. - The company plans to increase its investment in environmental protection and safety measures, which may lead to higher costs but aims to meet stringent regulatory standards[147].

联化科技股份有限公司 2023 年度内部控制评价报告 联化科技股份有限公司 2023 年度内部控制评价报告 联化科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求，结 合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对 2023 年 12 月 31 日公司财务报告内部控制有效性进行了评 价。 一、 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内 部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监 事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈 述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信 息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有 局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导致内 部控制变得不恰当，或对控制政 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-020 联化科技股份有限公司 第八届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第八届董事会第十五次会议通 知于2024年4月15日以电子邮件方式发出。会议于2024年4月25日在联化科技会议 室以现场与通讯表决相结合的方式召开。会议应出席董事7人，实际出席董事7人。 公司监事、高级管理人员列席了本次会议，会议由董事长王萍女士召集和主持， 符合《公司法》、《证券法》等法律法规、部门规章、规范性文件及《公司章程》 的有关规定。会议形成如下决议： 一、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过《2023年 度总裁工作报告》。 二、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过《2023年 度董事会工作报告》。 此议案需提交2023年度股东大会审议。 《 2023 年 度 董 事 会 工 作 报 告 》 的 具 体 内 容 详 见 披 露 于 巨 潮 资 讯 网 （www.cninfo.com.cn）上的公司 ...

2023 企业社会责任报告 Corporate Social Responsibility Report 2023 联化科技股份有限公司2023年度社会责任报告 Lianhetech 2023 Corporate Social Responsibility Report 目 录 专利信息 一流的研究 客户权益保护 阳光与绿色采购 质量与合规战略 客户权益保护 内部环境保护体系的建设 强制性清洁生产 应急预案 碳中和 员工多样性 员工培训 员工安全 员工即家人 员工活动 联化科技股份有限公司2023年度社会责任报告 Lianhetech 2023 Corporate Social Responsibility Report 报告编制说明 本报告是联化科技股份有限公司发布的第十三份社会责任报告，报告回顾了公 司 2023 年所面临的机遇与挑战，披露了公司履行经济、环保和社会责任等方面的理 念、践行和成绩。 本报告参照全球报告倡议组织《可持续发展报告指南（GRI）》及相关补充指引 条款，同时遵循深圳证券交易所《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》、《深圳证券交易所上市公司自律监管 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-026 联化科技股份有限公司 关于开展资产池业务的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）于2024年4月25日召开的第八届 董事会第十五次会议审议通过了《关于开展资产池业务的议案》，同意公司及控 股子公司共享不超过15亿元的资产池额度，资产池业务的开展期限为自股东大会 审议通过本议案之日起至下一年度股东大会召开之日止，业务期限内，上述额度 可滚动使用。具体每笔发生额提请公司股东大会授权公司董事长根据公司和控股 子公司的经营需要按照系统利益最大化原则确定。该事项须提交公司股东大会审 议通过后方可生效。现将有关事项公告如下： 一、资产池业务情况概述 公司及控股子公司共享不超过15亿元的资产池额度，即用于与所有合作银行 开展资产池业务的质押、抵押的资产对应业务余额不超过人民币15亿元，业务期 限内，该额度可滚动使用。具体每笔发生额提请公司股东大会授权公司董事长根 据公司和控股子公司的经营需要按照系统利益最大化原则确定。 5、担保方式 在风险可控的前 ...

联化科技股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国 有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 联化科技股份有限公司（以下简称"公司"）于2024年4月25日召开的第八届 董事会第十五次会议，审议通过了《关于续聘会计师事务所的议案》，同意公司 继续聘任立信会计师事务所（特殊普通合伙）为公司2024年度审计机构。上述事 项尚需提交股东大会审议。现将相关事项公告如下： 一、 拟续聘会计师事务所的基本情况 （一）、机构信息 证券代码：002250 证券简称：联化科技 公告编号：2024-024 1、基本信息 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗潘 序伦博士于1927年在上海创建，1986年复办，2010年成为全国首家完成改制的特 殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立 信是国际会计网络BDO的成员所，长期从事证券服务业务，新证券法实施前具有 证券、 ...

联化科技股份有限公司 2023年度 营业收入扣除情况表的鉴证报告 关于联化科技股份有限公司 2023年度 营业收入扣除情况表的鉴证报告 信会师报字[2024]第ZA12396号 联化科技股份有限公司全体股东： 联化科技管理层的责任是按照《深圳证券交易所股票上市规则》 和《深圳证券交易所上市公司自律监管指南第1号——业务办理》的相 关规定编制营业收入扣除情况表，确保营业收入扣除情况表真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏。 一、管理层的责任 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对营业收入扣除情况表 发表鉴证结论。 鉴证报告 第 1 页 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第3101号——历史 财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。该准 则要求我们遵守职业道德规范，计划和实施鉴证工作，以对营业收入 扣除情况表是否在所有重大方面按照《深圳证券交易所股票上市规 则》、《深圳证券交易所上市公司自律监管指南第1号——业务办理》的 相关规定编制获取合理保证。在执行鉴证工作过程中，我们实施了包 括询问、检查会计记录等我们认为必要的程序。我们相信，我们的 ...

联化科技股份有限公司 对外担保管理办法 第一章 总则 第一条 为了规范联化科技股份有限公司（以下简称"公司"）的对外担保 行为，有效控制担保风险，保护股东和其他利益相关者的合法权益，根据《中 华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国民法典》（以 下简称"《民法典》"）及中国证券监督管理委员会《上市公司监管指引第 8 号— —上市公司资金往来、对外担保的监管要求》、深圳证券交易所《深圳证券交易 所股票上市规则》（以下简称"《股票上市规则》"）《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》（以下简称"《规范运作》"）及 《联化科技股份有限公司章程》（以下简称"《公司章程》"）之规定，制订本办 法。 第二条 本办法所称下属子公司，是指公司拥有实际控制权的子公司。 第三条 本办法所称"对外担保"，是指公司为他人提供的担保，包括公司 对控股子公司的担保，包括为他人提供的保证、抵押或质押。具体种类包括人 民币/外币贷款、信用证开证、进出口押汇、打包贷款、银行保函、融资租赁 等）。上市公司及其控股子公司的对外担保总额，是指包括上市公司对控股子公 司担保在内的上市公司对外担保 ...

Financial Performance - The company's revenue for Q1 2024 was ¥1,465,597,404.32, a decrease of 25.12% compared to ¥1,957,286,746.09 in the same period last year[5] - Net profit attributable to shareholders was ¥2,691,631.55, down 93.96% from ¥44,586,378.55 year-on-year[5] - Basic and diluted earnings per share were both ¥0.003, representing a 94.00% decrease compared to ¥0.05 in the same period last year[5] - Total operating revenue for Q1 2024 was ¥1,465,597,404.32, a decrease of 25.1% compared to ¥1,957,286,746.09 in the same period last year[18] - Net profit for Q1 2024 was ¥24,235,708.40, a decline of 57.8% compared to ¥57,570,864.74 in Q1 2023[20] - Other comprehensive income after tax for Q1 2024 was ¥1,735,453.81, down from ¥3,468,954.67 year-over-year[20] Cash Flow - The net cash flow from operating activities was ¥4,025,709.35, a significant decline of 98.27% from ¥232,773,328.32 in the previous year[5] - The net cash flow from operating activities for the current period is 4,025,709.35, a significant decrease of 98.3% compared to 232,773,328.32 in the previous period[22] - Total cash inflow from operating activities decreased to 1,152,711,925.02, down 50.9% from 2,346,423,674.88 in the previous period[22] - Cash outflow from operating activities also decreased to 1,148,686,215.67, down 45.5% from 2,113,650,346.56 in the previous period[22] - The net cash flow from investing activities is -264,620,183.35, worsening from -219,472,318.13 in the previous period[23] - Cash inflow from financing activities increased to 1,009,108,463.20, up 9.9% from 917,507,951.10 in the previous period[23] - The net cash flow from financing activities improved to 321,454,706.11, compared to 92,290,482.39 in the previous period[23] - The ending balance of cash and cash equivalents increased to 656,602,349.68, up from 567,822,192.58 in the previous period[23] - Cash received from other investment activities was 10,000,000.00, down 49.3% from 19,768,051.85 in the previous period[22] - Total cash outflow from investing activities increased to 274,620,183.35, up from 239,240,369.98 in the previous period[22] - The company’s cash flow from operating activities indicates a need for strategic adjustments to improve liquidity and operational efficiency moving forward[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,981,536,928.97, an increase of 0.54% from ¥13,907,013,976.85 at the end of the previous year[5] - The company's equity attributable to shareholders decreased by 1.05% to ¥6,374,151,923.03 from ¥6,441,634,199.75 at the end of the previous year[5] - Total liabilities rose to ¥7,236,438,026.04, up from ¥7,148,634,166.34, indicating an increase of 1.2%[17] - The equity attributable to shareholders of the parent company decreased to ¥6,374,151,923.03 from ¥6,441,634,199.75, a drop of 1.0%[17] - The company reported a decrease in long-term equity investments to CNY 94,413,607.84 from CNY 95,026,781.76[15] Operational Insights - The company reported a significant drop in cash received from sales, totaling ¥1,054,995,129.12, down 43.87% from ¥1,879,602,203.12 year-on-year[8] - Other income increased by 270.18% to ¥14,846,207.39, primarily due to fluctuations in government subsidies received[8] - The company experienced a 584.25% decline in investment income, reporting a loss of ¥15,021,018.48 due to losses from forward instruments[8] - The company plans to continue focusing on operational adjustments and exploring new market opportunities to improve performance in the upcoming quarters[5] - The company is focusing on expanding its market presence and enhancing product development strategies[14] - The report indicates that there are no significant changes in the top 10 shareholders' equity positions[12] - The company has not disclosed any new mergers or acquisitions in the current quarter[14] Research and Development - Research and development expenses for Q1 2024 were ¥72,185,914.55, a decrease of 30.2% compared to ¥103,353,730.08 in Q1 2023[18]

联化科技股份有限公司 关联交易决策制度 第一章 总则 第一条 为保证联化科技股份有限公司（以下简称"公司"）与各关联方发 生的关联交易的公允性、合理性；以及公司各项业务的顺利开展并依法进行，依 据《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证券交易所 股票上市规则》（以下简称"《股票上市规则》"）和《联化科技股份有限公司 章程》（以下简称"《公司章程》"）等规定，制定本制度。 第二章 关联交易和关联人 第二条 公司的关联交易，是指公司或公司控股子公司与公司关联人之间 发生的转移资源或义务的事项，包括： 1 （一）购买或出售资产； （二）对外投资（含委托理财、对子公司投资等）； （三）提供财务资助（含委托贷款等）； （四）提供担保（含对控股子公司担保，反担保除外）； （五）租入或租出资产； （六）签订管理方面的合同（含委托经营、受托经营等）； （七）赠与或受赠资产； （八）债权或债务重组； （九）研究与开发项目的转让或受让； （十）签订许可协议； （十一）购买原材料、燃料、动力； （十二）销售产品、商品； （十三）提供或接受劳务； （十四）委托或受托销售； （十五）与关联人共同投资； （十六）存贷 ...